VBD Mod Oncho Elimination Platform

Onchocerciasis · river blindness · Tanzania

From survey results to stop-MDA decisions

Check Ov16 serology and O-150 fly surveys against the WHO thresholds, project how long ivermectin, moxidectin and vector control need to run, and record how ready a focus is to stop treatment.

Research tool, not a decision-making authority. The WHO 2016 guidelines and Tanzania's national onchocerciasis elimination expert committee remain the authority for any stop-MDA decision. Model projections come from a manuscript under peer review and describe typical settings, not any named focus. The platform holds no programme data.

Stop-MDA threshold checks

Is the survey below the WHO threshold?

A survey passes only if the upper end of the one-sided 95% exact confidence interval, not the observed prevalence, is below the threshold. Enter the survey counts; everything is calculated in your browser.

Example values
WHO asks for children under 10 years tested by Ov16 ELISA. The 1% rule is the review's sensitivity analysis, which also accepts rapid tests.
upper = qbeta(0.95, x + 1, n − x)  ·  x = 0: 1 − 0.05^(1/n)
Observed seroprevalence
Upper 95% bound (one-sided)
Observed value (black line), 95% interval (bar) and threshold (red dashed line)
0%

Transmission model · scenario explorer

How long must treatment continue?

Projections from a deterministic model that links human and Simulium populations with adult worms, skin microfilariae and the pharmacokinetics of ivermectin and moxidectin. Choose a transmission setting, coverage and up to five strategies.

Share of the whole population treated each round. Vector control alone does not depend on it.

Skin-snip microfilarial prevalence

% of the population, by years since the first round

Infective flies

Per 1,000 flies; dashed line is the WHO threshold (0.5 per 1,000)

Years of intervention needed

Elimination means skin-snip mf prevalence below 1% and infective flies below 1 in 2,000, both still met 20 years after all interventions stop.

StrategyYears neededFlies below WHO thresholdmf prevalence below 1%

Source: Mweya CN, Moxidectin, ivermectin and vector control for onchocerciasis elimination: a transmission model with within-host parasite and drug dynamics (under peer review). Strategies marked optimistic assume moxidectin kills 35% of adult worms per dose, which trials have not shown.

Elimination-readiness scorecard · template

How ready is a focus to stop treatment?

Ten criteria and one warning flag, each rated on the documented evidence with a grade for its quality. There is no total score: the criteria are not equally important, so each focus gets a profile and a stage. Your entries stay in this browser.

Tanzania

Onchocerciasis foci

Seven transmission foci, with the year community-directed treatment with ivermectin (CDTI) began. Focus-by-focus ratings will be added when the systematic review is published.

CodeFocusDistricts (about 2012 boundaries)CDTI startYears by 2026Scorecard

District lists are provisional and overstate the transmission area. Systematic review protocol: OSF 10.17605/OSF.IO/D2H83.

How it works

Three kinds of evidence, kept apart

Survey results, model projections and documented programme evidence answer different questions. The platform shows them side by side and never merges them into one number.

STEP 1

Survey results

Ov16 serology in children and O-150 PCR in flies are compared with the WHO thresholds using exact one-sided 95% bounds.

STEP 2

Transmission model

Human, fly, worm and drug dynamics, calibrated to clinical trial data and compared with elimination results from Mali and Senegal.

STEP 3

Readiness scorecard

Ten criteria rated on documented evidence, each with a quality grade: A peer-reviewed, B programme report, C indirect or modelled.

STEP 4

Expert decision

The national expert committee weighs all three. Model results enter only as grade C evidence.

Science and software

Sources

Guideline

World Health Organization (2016). Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures. Geneva: WHO.

Model

Mweya CN. Moxidectin, ivermectin and vector control for onchocerciasis elimination: a transmission model with within-host parasite and drug dynamics. Under peer review

Review

Onchocerciasis elimination in Tanzania, focus by focus: a systematic review and elimination-readiness scorecard, 1995–2026. Protocol registered on OSF, 10.17605/OSF.IO/D2H83. In progress

Statistics

Exact one-sided 95% bounds by the Clopper–Pearson method; fly prevalence from pool screening with equal pool sizes.

Licence

Open source. Platform software and model code are to be released under GPL-3.0-or-later.

Access and collaboration

Work with the platform

The calculators, scenarios and scorecard template are open to everyone. Programmes, researchers and students interested in focus-level analyses, validation or collaboration can write with the subject line “Oncho platform”.

mweya.clement@udsm.ac.tz